First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial - Quiz - MDSpire

First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial

  • By

  • Eusebio Luna Velasquez

  • Renil S. Titus

  • David-Dan Nguyen

  • Carlos Riveros

  • Aly-Khan Lalani

  • Dharam Kaushik

  • Guru P. Sonpavde

  • Petros Grivas

  • Christopher J. D. Wallis

  • Raj Satkunasivam

  • July 1, 2026

  • 0 min

Share

Original Source(s)

First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial

  • by Eusebio Luna Velasquez, Renil S. Titus, David-Dan Nguyen, Carlos Riveros, Aly-Khan Lalani, Dharam Kaushik, Guru P. Sonpavde, Petros Grivas, Christopher J. D. Wallis, Raj Satkunasivam

  • July 1, 2026

Related Content

Machine learning-assisted prognosis prediction and surgical decision-making for glioblastoma: perceived benefits and concerns of patients, caregivers, and neurosurgeons

Crucial role of IL-6, IL-8, IL-11 and leptin in tumor microenvironment in a group of patients with GEP-NETs- crosstalk between inflammation and cancer

Radiomics-Based AI for the Diagnosis and Prognosis of Vessels Encapsulating Tumor Clusters in Hepatocellular Carcinoma: Systematic Review and Meta-Analysis